PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

Summary
Coronary artery disease (CAD), which precipitates acute coronary syndrome (ACS), is the most common type of cardiovascular disease (CVD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). At present, the cardiovascular (CV) drug market is well established and boasts a multitude of branded and generic drug choices to treat the major conditions associated with ACS: thrombosis (fibrinolytics, anticoagulants, and antiplatelets), hypercholesterolemia/atherosclerosis (statins and PCSK9 inhibitors), and hypertension (renin angiotensin aldosterone system (RAAS) inhibitors and beta blockers). Due to this range of sub-indications and the recent increase in disease prevalence, it is evident that ACS represents a potentially lucrative market for Big Pharma to explore.

It is estimated that sales of acute coronary syndrome (ACS) therapeutics to be approximately $7.8B across the 7MM in 2015, including the US, the five major European markets (5EU: France, Germany, Italy, Spain, and UK), and Japan. In the 2015 base year 10% of market share were attributed to the acute phase sales ($714M) and 90% to the chronic phase ($7.0B). By 2025, the ACS market to grow at a strong Compound Annual Growth Rate (CAGR) of 4.6%, reaching sales of $12.1B by the end of the forecast period. This is mainly attributed to the chronic phase growth, which is forecast to reflect a CAGR of 5.0%, reaching $11.4B in sales by 2025 (94% of market share).

As per Michela J. McMullan, Analyst: “At present, a large proportion of patients with clinical atherosclerotic cardiovascular disease cannot reach guideline recommended levels of LDL-C with the standard of care therapies, which leads to recurrent ACS events.

Major drivers of ACS market growth over the forecast period are the -
- Launches of the first PCSK9 inhibitors, Repatha (evolocumab) and Praluent (alirocumab), in the US (2015), EU (2015), and Japan (2016); and positive results from their cardiovascular (CV) outcomes trials.
- Launch of first-in-class lipid-lowering adenosine triphosphate-citrate lyase (ACL) inhibitor/ adenosine monophosphate-activated protein kinase (AMPK) activator, ETC-1002, in 2021.
- Increase in the global prevalence of ACS.

The report “PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025” provides overview of ACS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

In depth, this report provides the following analysis -
- Annualized ACS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ACS therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global ACS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Amgen, AstraZeneca, Bristol-Myers Squibb, Cerenis Therapeutics, CSL Limited, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, Janssen Pharmaceuticals, (Johnson & Johnson), The Medicines Company, Merck, Pfizer, Sanofi

Highlights
Key Questions Answered
- The new generation antiplatelets, Brilinta and Effient will see a significant increase in patient shares for the treatment ACS against the previous cornerstone, clopidogrel. However, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the ACS market?
- The PCSK9 inhibitors recently launched into the CV market, and these are predicted to have a notable impact in the ACS space once their CV outcomes data is shown. The most notable candidate in the current late-stage ACS pipeline is ETC-1002, which is vying to target the needed statin intolerant ACS population. Will these newly marketed and late-stage drugs make a significant impact on the ACS market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
- We have seen a notable increase in the ACS population in terms of diagnosed prevalent ACS cases , as well as ACS hospitalisations (incidence and recurrent events). How will epidemiological changes impact the growth of the future market?

Key Findings
- The main driver of the significant expansion of the ACS market will be the increase in use and physician confidence in the PCSK9 inhibitor class, which will hold four major players by the end of this forecast. Novel lipid lowering therapy, ETC-1002, will also be a major contributor, vying to steal majority of patient shares for the statin intolerant ACS population by the end of this forecast.
- The major global barrier for the ACS market will be the generic erosion of the key antiplatelet therapies, Brilinta and Effient by the end of this forecast. Both drugs will pick up significant momentum in sales prior to patent expiry.
- The dynamics of the ACS market will shift greatly towards solving the atherosclerotic burden associated in ACS from the historical strategy of developing antithrombotic therapies.
- The key market opportunities lie in addressing unmet needs through the development of optimal agents for secondary prevention by controlling lipid levels and repairing the damaged myocardium post myocardial infarction to prevent comorbidities such as heart failure.

Scope
- Overview of ACS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized ACS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ACS therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global ACS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global ACS therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ACS therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global ACS therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

1 Table of Contents 10
1.1 List of Tables 16
1.2 List of Figures 22

2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 25
2.3 Upcoming Related Reports 25

3 Disease Overview 26
3.1 Etiology and Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology 31
3.2 Classification or Staging Systems 33
3.3 Symptoms 34
3.4 Prognosis 35
3.5 Quality of Life 36

4 Epidemiology 37
4.1 Disease Background 37
4.2 Risk Factors and Comorbidities 38
4.3 Global Trends 41
4.3.1 ACS Diagnosed Prevalence 41
4.3.2 STEMI and NSTEMI Trends 44
4.3.3 ACS Hospitalizations 45
4.4 Forecast Methodology 47
4.4.1 Sources Used 50
4.4.2 Forecast Assumptions and Methods 57
4.4.3 Sources Not Used 70
4.5 Epidemiological Forecast for ACS (2015-2025) 71
4.5.1 Diagnosed Prevalent Cases of ACS 71
4.5.2 Age-Specific Diagnosed Prevalent Cases of ACS 73
4.5.3 Sex-Specific Diagnosed Prevalent Cases of ACS 75
4.5.4 Diagnosed Prevalent Cases of ACS Segmented by STEMI, NSTEMI, and UA 77
4.5.5 Age-Standardized Diagnosed Prevalence of ACS 79
4.5.6 ACS Hospitalizations 80
4.5.7 Sex-Specific ACS Hospitalizations 82
4.5.8 ACS Hospitalizations Segmented by STEMI, NSTEMI, and UA 84
4.6 Discussion 86
4.6.1 Epidemiological Forecast Insight 86
4.6.2 Limitations of the Analysis 87
4.6.3 Strengths of the Analysis 88

5 Disease Management 90
5.1 Diagnosis and Treatment Overview 90
5.1.1 Diagnosis 90
5.1.2 Treatment Guidelines and Leading Prescribed Drugs 91
5.1.3 Clinical Practice 96
5.2 US 99
5.3 5EU 102
5.4 Japan 106

6 Competitive Assessment 109
6.1 Overview 109
6.2 Product Profiles - Acute Coronary Syndrome 112
6.2.1 Antihypertensives 112
6.2.2 Anticoagulants 130
6.2.3 Fibrinolytics 150
6.2.4 Antidyslipidemics 155
6.2.5 Antiplatelets 176

7 Unmet Need and Opportunity 209
7.1 Overview 209
7.2 Management of ACS in Elderly Patients 210
7.2.1 Unmet Need 210
7.2.2 Gap Analysis 211
7.2.3 Opportunity 212
7.3 Blood Thinning Agent with Reduced Bleeding 213
7.3.1 Unmet Need 213
7.3.2 Gap Analysis 214
7.3.3 Opportunity 214
7.4 Therapies that Treat Fibrotic Myocardium and Associated Comorbidities 215
7.4.1 Unmet Need 215
7.4.2 Gap Analysis 216
7.4.3 Opportunity 217
7.5 Achieving Guideline-Recommended Levels of LDL-C 217
7.5.1 Unmet need 217
7.5.2 Gap Analysis 218
7.5.3 Opportunity 219
7.6 Optimal Treatment of ACS Patients with Hyperglycemia 220
7.6.1 Unmet Need 220
7.6.2 Gap Analysis 220
7.6.3 Opportunity 221

8 Pipeline Assessment 222
8.1 Overview 222
8.2 Promising Drugs in Clinical Development 224
8.2.1 Bococizumab 225
8.2.2 Anacetrapib 231
8.2.3 CSL-112 238
8.2.4 CER-001 246
8.2.5 LY3015014 253
8.2.6 AMG-899 257
8.2.7 ETC-1002 262

9 Current and Future Players 268
9.1 Overview 268
9.2 Trends in Corporate Strategy 273
9.3 Company Profiles 275
9.3.1 Amgen 275
9.3.2 AstraZeneca 277
9.3.3 Bristol-Myers Squibb 279
9.3.4 Cerenis Therapeutics 281
9.3.5 CSL Limited 282
9.3.6 Daiichi Sankyo 284
9.3.7 Eli Lilly 286
9.3.8 Esperion Therapeutics 287
9.3.9 GlaxoSmithKline 288
9.3.10 Janssen 290
9.3.11 The Medicines Company 291
9.3.12 Merck & Co. 294
9.3.13 Pfizer 296
9.3.14 Sanofi 298

10 Market Outlook 301
10.1 Global Market 301
10.1.1 Forecast 301
10.1.2 Drivers and Barriers - Global Issues 308
10.2 United States 313
10.2.1 Forecast 313
10.2.2 Key Events 318
10.2.3 Drivers and Barriers 318
10.3 France 320
10.3.1 Forecast 320
10.3.2 Key Events 325
10.3.3 Drivers and Barriers 325
10.4 Germany 326
10.4.1 Forecast 326
10.4.2 Key Events 331
10.4.3 Drivers and Barriers 332
10.5 Italy 333
10.5.1 Forecast 333
10.5.2 Key Events 338
10.5.3 Drivers and Barriers 339
10.6 Spain 340
10.6.1 Forecast 340
10.6.2 Key Events 344
10.6.3 Drivers and Barriers 344
10.7 United Kingdom 345
10.7.1 Forecast 345
10.7.2 Key Events 350
10.7.3 Drivers and Barriers 350
10.8 Japan 352
10.8.1 Forecast 352
10.8.2 Key Events 356
10.8.3 Drivers and Barriers 356

11 Appendix 359
11.1 Bibliography 359
11.2 Abbreviations 389
11.3 Methodology 396
11.4 Forecasting Methodology 396
11.4.1 Diagnosed Acute Coronary Syndrome Patients 396
11.4.2 Percent Drug-Treated Patients 397
11.4.3 Drugs Included in Each Therapeutic Class 397
11.4.4 Launch and Patent Expiry Dates 398
11.4.5 General Pricing Assumptions 399
11.4.6 Individual Drug Assumptions 400
11.4.7 Generic Erosion 408
11.4.8 Pricing of Pipeline Agents 409
11.5 Physicians and Specialists Included in this Study 410
11.6 About the Authors 413
11.6.1 Analyst 413
11.6.2 Therapy Area Director 413
11.6.3 Epidemiologist 414
11.6.4 Global Director of Therapy and Epidemiology 414
11.7 About GlobalData 415
11.8 Disclaimer 415

1.1 List of Tables
Table 1: Marketed Antiplatelet Agents that Inhibit Platelet Activation 29
Table 2: Marketed Anticoagulants that Inhibit the Coagulatory Cascade 29
Table 3: Antidyslipidemic agents 31
Table 4: Classifications of ACS 33
Table 5: Universal Classification of MI 34
Table 6: Symptoms of Acute Coronary Syndrome 35
Table 7: Risk Factors and Comorbidities for ACS 40
Table 8: Global, Crude Total Population Prevalence Percentages of Angina Pectoris and Mean Age of Study Participants 44
Table 9: 7MM, Sources of Diagnosed Prevalence Data for MI 51
Table 10: 7MM, Data Sources of STEMI and NSTEMI Proportions Among Diagnosed Prevalent Cases of MI 52
Table 11: 7MM, Data Sources of ACS Hospitalizations 54
Table 12: 7MM, Data Sources of STEMI and NSTEMI Proportions Among MI Hospitalizations 56
Table 13: 7MM, Diagnosed Prevalent Cases of ACS, Ages ?25 Years, Both Sexes, N, Select Years, 2015-2025 72
Table 14: 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N (Row %), 2015 74
Table 15: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages ?25 Years, N (Row %), 2015 76
Table 16: 7MM, Diagnosed Prevalent Cases of STEMI, NSTEMI, and UA, Ages ?25 Years, N (Row %), 2015 78
Table 17: 7MM ACS Hospitalizations, Ages ?25 Years, Both Sexes, N, Select Years, 2015-2025 81
Table 18: 7MM, Sex-Specific ACS Hospitalizations, Ages ?25 Years, N (Row %), 2015 83
Table 19: 7MM, Diagnosed ACS Hospitalizations Segmented by STEMI, NSTEMI and UA, Ages ?25 Years, Both Sexes, N, 2015 85
Table 20: Most-Prescribed Drugs for ACS by Class in the Global Markets, 2015 92
Table 21: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI) 94
Table 22: Country Profile for ACS - US 101
Table 23: Country Profile for ACS - 5EU 104
Table 24: Country Profile for ACS - Japan 107
Table 25: Leading Treatments for ACS, 2015 110
Table 26: Commonly Used Beta Blockers 113
Table 27: Product Profile - Beta Blockers 114
Table 28: Beta Blockers SWOT Analysis, 2015 116
Table 29: Global ACS Sales Forecasts [$m] for Beta Blockers, 2015-2025 117
Table 30: Commonly Used ACE Inhibitors 118
Table 31: Product Profile - ACE Inhibitors 119
Table 32: ACE Inhibitor?SWOT Analysis, 2015 121
Table 33 Global ACS Sales Forecasts [$m] for ACE inhibitors, 2015-2025 122
Table 34: Commonly Used ARBs 123
Table 35: Product Profile - Angiotensin Receptor Blockers (ARBs) 123
Table 36: ARB SWOT Analysis, 2015 125
Table 37: Global ACS Sales Forecasts [$m] for ARBs, 2015-2025 126
Table 38: Product Profile - Mineralocorticoid Receptor Antagonists (MRAs) 127
Table 39: MRA SWOT Analysis, 2016 129
Table 40: Global ACS Sales Forecasts [$m] for MRAs, 2015-2025 130
Table 41: Product Profile - Warfarin 132
Table 42: Warfarin SWOT Analysis, 2015 134
Table 43: Global ACS Sales Forecasts [$m] for Warfarin, 2015-2025 135
Table 44: Product Profile - Angiomax 136
Table 45: AngiomaxSWOT Analysis, 2015 138
Table 46: Global ACS Sales Forecasts [$m] for Angiomax, 2015-2025 139
Table 47: Product Profile - Fondaparinux 141
Table 48: Arixtra SWOT Analysis, 2015 143
Table 49: Global ACS Sales Forecasts ($M) for Fondaparinux, 2015-2025 144
Table 50: Product Profile - Xarelto (rivaroxaban) 147
Table 51: Xarelto SWOT Analysis, 2015 149
Table 52: Global ACS Sales Forecast ($M) for Xarelto, 2015-2025 150
Table 53: Commonly Used tPAs 152
Table 54: Product Profile - Tissue Plasminogen Activator (tPA) 152
Table 55: Fibrinolytics?SWOT Analysis, 2015 154
Table 56: Global ACS Sales Forecast ($M) for Fibrinolytics, 2015-2025 155
Table 57: Product Profile - Repatha (Evolocumab) 158
Table 58: Product Profile - Praluent (Alirocumab) 159
Table 59: PCSK9 inhibitors SWOT Analysis, 2015 161
Table 60: Global ACS Sales Forecasts [$m] for Repatha, 2015-2025 162
Table 61: Global ACS Sales Forecasts [$m] for Praluent, 2015-2025 163
Table 62: Product Profile - Atorvastatin 166
Table 63: Product Profile - Simvastatin 167
Table 64: Lipitor (Atorvastatin) SWOT Analysis, 2015 170
Table 65: Zocor (Simvastatin) SWOT Analysis, 2015 171
Table 66: Global ACS Sales Forecasts [$m] for Generic Statins, 2015-2025 172
Table 67: Product Profile - Crestor (Rosuvastatin) 173
Table 68: Crestor (Rosuvastatin) SWOT Analysis, 2015 175
Table 69: Global ACS Sales Forecasts [$m] for Crestor, 2015-2025 176
Table 70: Product Profile - Clopidogrel 178
Table 71: Clopidogrel SWOT Analysis, 2015 180
Table 72: Global ACS Acute Phase Sales Forecast ($M) for Clopidogrel, 2015-2025 181
Table 73: Global ACS Chronic Phase Sales Forecasts ($M) for Clopidogrel, 2015-2025 182
Table 74: Product Profile - Brilinta (ticagrelor) 184
Table 75: Brilinta (ticagrelor) SWOT Analysis, 2015 186
Table 76: Global Acute Phase ACS Sales Forecast ($M) for Brilinta, 2015-2025 187
Table 77: Global ACS Chronic Phase Sales Forecast ($M) for Brilinta, 2015-2025 188
Table 78: Product Profile - Effient (Prasugrel) 190
Table 79: Effient (Prasugrel) SWOT Analysis, 2015 192
Table 80: Global Acute Phase ACS Sales Forecast ($M) for Effient, 2015-2025 193
Table 81: Global ACS Chronic Phase Sales Forecast ($M) for Effient, 2015-2025 193
Table 82: Product Profile - Integrilin (Eptifibatide) 195
Table 83: Integrilin (Eptifibatide) SWOT Analysis, 2015 197
Table 84: Global ACS Sales Forecast ($M) for Integrilin, 2015-2025 198
Table 85: Product Profile - Cangrelor 200
Table 86: Kengreal (cangrelor) SWOT Analysis, 2015 202
Table 87: Global ACS Sales Forecasts ($M) for Kengreal, 2015-2025 203
Table 88: Product Profile - Zontivity (Vorapaxar) 205
Table 89: Vorapaxar SWOT Analysis, 2015 207
Table 90: Global ACS Sales Forecast ($M) for Zontivity, 2015-2025 208
Table 91: Unmet Need and Opportunity in ACS 210
Table 92: Comparison of Therapeutic Classes in Development for ACS, 2015 224
Table 93: Comparison of Therapeutic Classes in Pipeline for ACS, 2016 225
Table 94: Product Profile - Bococizumab (PF-04950615) 227
Table 95: Bococizumab (PF-04950615) SWOT Analysis, 2015 230
Table 96: Global ACS Sales Forecasts [$m] for Bococizumab, 2015-2025 231
Table 97: Product Profile - Anacetrapib 234
Table 98: Anacetrapib SWOT Analysis, 2015 237
Table 99: Global ACS Sales Forecasts [$m] for Anacetrapib, 2015-2025 238
Table 100: Product Profile - CSL-112 241
Table 101: CSL-112 SWOT Analysis, 2015 244
Table 102: Global ACS Sales Forecasts [$m] for CSL-112, 2015-2025 245
Table 103: Product Profile - CER-001 248
Table 104: CER-001 SWOT Analysis, 2015 251
Table 105: Global ACS Sales Forecasts [$m] for CER-001, 2015-2025 252
Table 106: Product Profile - LY3015014 254
Table 107: LY3015014 SWOT Analysis, 2015 256
Table 108 Global ACS Sales Forecasts [$m] for LY3015014 , 2015-2025 257
Table 109: Product Profile - AMG-899 259
Table 110: AMG-899 SWOT Analysis, 2015 261
Table 111: Global ACS Sales Forecasts [$m] for AMG-899, 2015-2025 262
Table 112: Product Profile - ETC-1002 264
Table 113: ETC-1002 SWOT Analysis, 2016 266
Table 114: Global ACS Sales Forecasts [$m] for ETC-1002, 2015-2025 267
Table 115: Key Companies in the ACS Market, 2016 272
Table 116: Amgen's ACS Portfolio Assessment, 2016 276
Table 117: AstraZeneca's ACS Portfolio Assessment, 2015 279
Table 118: BMS's ACS Portfolio Assessment, 2015 281
Table 119: Cerenis' ACS Portfolio Assessment, 2015 282
Table 120: CSL Limited's ACS Portfolio Assessment, 2015 283
Table 121: Daiichi Sankyo's ACS Portfolio Assessment, 2015 285
Table 122: Eli Lilly's ACS Portfolio Assessment, 2015 287
Table 123: Esperion's ACS Portfolio Assessment, 2016 288
Table 124: GlaxoSmithKline's Acute Coronary Syndrome Portfolio Assessment, 2015 290
Table 125: Janssen's ACS Portfolio Assessment, 2015 291
Table 126: The Medicines Company's Acute Coronary Syndrome Portfolio Assessment, 2015 294
Table 127: Merck's ACS Portfolio Assessment, 2015 296
Table 128: Pfizer's ACS Portfolio Assessment, 2015 298
Table 129: Sanofi's ACS Portfolio Assessment, 2015 300
Table 130: Global Sales Forecasts [$m] for Acute Coronary Syndrome, 2015-2025 304
Table 131: ACS Global market - Drivers and Barriers, 2015-2025 308
Table 132: Sales Forecasts [$m] for Acute Coronary Syndrome in the US, 2015-2025 315
Table 133: Key Events Impacting Sales for ACS in the US, 2015-2025 318
Table 134: US ACS Market - Drivers and Barriers, 2015-2025 318
Table 135: Sales Forecasts [$m] for Acute Coronary Syndrome in France, 2015-2025 322
Table 136: Key Events Impacting Sales for ACS in France, 2015-2025 325
Table 137: France ACS market - Drivers and Barriers, 2015-2025 325
Table 138: Sales Forecasts [$m] for Acute Coronary Syndrome in Germany, 2015-2025 328
Table 139: Key Events Impacting Sales for ACS in Germany, 2015-2025 331
Table 140: Germany ACS market - Drivers and Barriers, 2015-2025 332
Table 141: Sales Forecasts [$m] for Acute Coronary Syndrome in Italy, 2015-2025 335
Table 142: Key Events Impacting Sales for ACS in Italy, 2015-2025 338
Table 143: Italy ACS market - Drivers and Barriers, 2015-2025 339
Table 144: Sales Forecasts [$m] for Acute Coronary Syndrome in Spain, 2015-2025 341
Table 145: Key Events Impacting Sales for ACS in Spain, 2015-2025 344
Table 146: Spain ACS Market - Drivers and Barriers, 2015-2025 344
Table 147: Sales Forecasts [$m] for Acute Coronary Syndrome in the UK, 2015-2025 347
Table 148: Key Events Impacting Sales for ACS in the UK, 2015-2025 350
Table 149: UK ACS market - Drivers and Barriers, 2015-2025 350
Table 150: Sales Forecasts [$m] for Acute Coronary Syndrome in Japan, 2015-2025 353
Table 151: Key Events Impacting Sales for ACS in Japan, 2015-2025 356
Table 152: Japan ACS Market - Drivers and Barriers, 2015-2025 356
Table 153: Key ACS Launch Dates 398
Table 154: Key Patent Expiries 398
Table 155: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 412

1.2 List of Figures
Figure 1: The ACS Timeline and the Scope of GlobalData's ACS Report and Forecast 27
Figure 2: Progression of CAD, Atherosclerotic Plaque Rupture, Thrombosis, and ACS 28
Figure 3: Platelet and Coagulatory Factors Implicated in Thrombosis 30
Figure 4: Electrocardiography in the Diagnosis of ACS 32
Figure 5: US, Germany, and UK, Crude Diagnosed MI Prevalence in Men and Women, 1990-2008 42
Figure 6: Global, Crude Total Population Prevalence Percentages of Angina Pectoris (%) 44
Figure 7: Case Segmentation Map 50
Figure 8: 7MM, Diagnosed Prevalent Cases of ACS, Ages ?25 Years, Both Sexes, N, Select Years, 2015-2025 73
Figure 9; 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N, 2015 75
Figure 10: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages ?25 Years, N, 2015 77
Figure 11: 7MM, Diagnosed Prevalent Cases of STEMI and NSTEMI, Ages ?25 Years, N, 2015 79
Figure 12: 7MM, Age-Standardized Diagnosed Prevalence of ACS, Ages ?25 Years, 2015 80
Figure 13: 7MM ACS Hospitalizations, Ages ?25 Years, Both Sexes, N, Select Years, 2015-2025 82
Figure 14: 7MM, Sex-Specific ACS, Ages ?25 Years, N, 2015 84
Figure 15: 7MM, Diagnosed ACS Hospitalizations Segmented by NSTEMI and STEMI, Ages ?25 Years, Both Sexes, N, 2015 86
Figure 16: Company Portfolio Gap Analysis in ACS, 2015-2025 271
Figure 17: Global Sales for ACS by Region, 2015-2025 306
Figure 18: Global Sales for ACS by Class, 2015-2025 307
Figure 19 Global Sales for PCSK9 inhibitors for ACS, 2015-2025 308
Figure 20: Sales for ACS in the US by Drug Class, 2015-2025 317
Figure 21: Sales for ACS in France by Drug Class, 2015-2025 324
Figure 22: Sales for ACS in Germany by Drug Class, 2015-2025 330
Figure 23: Sales for ACS in Italy by Drug Class, 2015-2025 337
Figure 24: Sales for ACS in Spain by Drug Class, 2015-2025 343
Figure 25: Sales for ACS in the UK by Drug Class, 2015-2025 349
Figure 26: Sales for ACS in Japan by Drug Class, 2015-2025 355

Companies Mentioned
• Amgen
• AstraZeneca
• Bristol-Myers Squibb
• Cerenis Therapeutics
• CSL Limited
• Daiichi Sankyo
• Eli Lilly
• Esperion Therapeutics
• GlaxoSmithKline
• Janssen
• The Medicines Company
• Merck & Co.
• Pfizer
• Sanofi